Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Long-term Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis With Phosphate Binders

NCT07285304 is registered in ClinicalTrials.gov with Taisho Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT07285304
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07285304 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Long-term Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis With Phosphate Binders
Lead sponsor
Taisho Pharmaceutical Co., Ltd.
Phase
Phase 3
Overall status
Recruiting
Start date
December 1, 2025
Completion date
July 31, 2027
Enrollment
300 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hyperphosphatemia patients on hemodialysis